⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INTS News
Intensity Therapeutics, Inc. Common stock
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
globenewswire.com
NTHI
TNGX
INTS
Form 8-K
sec.gov
INTS
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
INTS
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
prnewswire.com
INTS
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
prnewswire.com
INTS
Form 8-K
sec.gov
INTS
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
prnewswire.com
INTS
Form 8-K
sec.gov
INTS
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com
INTS
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
prnewswire.com
INTS